These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 14733708)

  • 21. The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice.
    Abe S; Watabe H; Takaseki S; Aihara M; Yoshitomi T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):55-60. PubMed ID: 23046436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bimatoprost and its free acid are prostaglandin FP receptor agonists.
    Sharif NA; Williams GW; Kelly CR
    Eur J Pharmacol; 2001 Dec; 432(2-3):211-3. PubMed ID: 11740958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the ocular hypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor selective prostaglandin analogs.
    Woodward DF; Chan MF; Burke JA; Cheng-Bennett A; Chen G; Fairbairn CE; Gac T; Garst ME; Gluchowski C; Kaplan LJ
    J Ocul Pharmacol; 1994; 10(1):177-93. PubMed ID: 8207325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of prostaglandin F2alpha, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter.
    Ansari HR; Kaddour-Djebbar I; Abdel-Latif AA
    Exp Eye Res; 2004 Feb; 78(2):285-96. PubMed ID: 14729360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies.
    Woodward DF; Lawrence RA; Fairbairn CE; Shan T; Williams LS
    J Lipid Mediat; 1993; 6(1-3):545-53. PubMed ID: 8358015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
    Woodward DF; Krauss AH; Chen J; Liang Y; Li C; Protzman CE; Bogardus A; Chen R; Kedzie KM; Krauss HA; Gil DW; Kharlamb A; Wheeler LA; Babusis D; Welty D; Tang-Liu DD; Cherukury M; Andrews SW; Burk RM; Garst ME
    J Pharmacol Exp Ther; 2003 May; 305(2):772-85. PubMed ID: 12606640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data.
    Sharif NA; Xu SX; Williams GW; Crider JY; Griffin BW; Davis TL
    J Pharmacol Exp Ther; 1998 Aug; 286(2):1094-102. PubMed ID: 9694973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
    Kiriyama M; Ushikubi F; Kobayashi T; Hirata M; Sugimoto Y; Narumiya S
    Br J Pharmacol; 1997 Sep; 122(2):217-24. PubMed ID: 9313928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bimatoprost (Lumigan((R))) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies.
    Sharif NA; Kelly CR; Williams GW
    Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):27-33. PubMed ID: 12538087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor.
    Sharif NA; Davis TL; Williams GW
    J Pharm Pharmacol; 1999 Jun; 51(6):685-94. PubMed ID: 10454045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.
    Hellberg MR; McLaughlin MA; Sharif NA; DeSantis L; Dean TR; Kyba EP; Bishop JE; Klimko PG; Zinke PW; Selliah RD; Barnes G; DeFaller J; Kothe A; Landry T; Sullivan EK; Andrew R; Davis AA; Silver L; Bergamini MV; Robertson S; Weiner AL; Sallee VL
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S13-33. PubMed ID: 12204698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Receptors involved in the mechanism of action of topical prostaglandines].
    Neacsu AM
    Oftalmologia; 2009; 53(2):3-7. PubMed ID: 19697832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys.
    Yamane S; Karakawa T; Nakayama S; Nagai K; Moriyuki K; Neki S; Suto F; Kambe T; Hirota Y; Kawabata K
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2547-52. PubMed ID: 25788650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells.
    Ooi YH; Oh DJ; Rhee DJ
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5259-65. PubMed ID: 19443729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription.
    Liang Y; Li C; Guzman VM; Chang WW; Evinger AJ; Pablo JV; Woodward DF
    Br J Pharmacol; 2004 Jun; 142(4):737-48. PubMed ID: 15159280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility.
    Thieme H; Schimmat C; Münzer G; Boxberger M; Fromm M; Pfeiffer N; Rosenthal R
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):938-45. PubMed ID: 16505027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular basis for bimatoprost effects on human conventional outflow.
    Stamer WD; Piwnica D; Jolas T; Carling RW; Cornell CL; Fliri H; Martos J; Pettit SN; Wang JW; Woodward DF
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5176-81. PubMed ID: 20435598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
    Nakajima T; Matsugi T; Goto W; Kageyama M; Mori N; Matsumura Y; Hara H
    Biol Pharm Bull; 2003 Dec; 26(12):1691-5. PubMed ID: 14646172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study.
    Griffin BW; Williams GW; Crider JY; Sharif NA
    J Pharmacol Exp Ther; 1997 May; 281(2):845-54. PubMed ID: 9152393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.